Evaluation of CD22 modulation as a mechanism of resistance to inotuzumab ozogamicin (InO): Results from central CD22 testing on the Children’s Oncology Group (COG) phase II trial of INO in children and young adults with CD22+ B-acute lymphoblastic leukemia (B-ALL).
Year: 2020
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: National Cancer Institute, Cincinnati Children's Hospital Medical Center, Center for Cancer Research, University of Southern California, Children's Oncology Group, Children's Hospital of Philadelphia, Children's Hospital Los Angeles, Baylor College of Medicine, University of Utah, Johns Hopkins University, University of Florida, University of Colorado Cancer Center, University of California, San Francisco
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Pfizer
OpenAlex ID: W3029132671